According to a notification posted on Health Canada’s website, Canada approved Pfizer Inc’s oral antiviral medication for treating mild to moderate cases of COVID-19 in adults aged 18 and older on Monday.
The Omicron variety has been linked to an increase in cases and hospitalizations in Canada, causing provinces to impose restrictions and the federal government to assist affected firms.
According to results from Pfizer’s clinical trial, Paxlovid, an antiviral regimen, was nearly 90% effective in reducing hospitalizations and deaths in individuals at high risk of severe illness. According to Pfizer, recent lab data indicates that the medication is still effective against Omicron.
Ottawa said last month that it had signed a deal with Pfizer for a million doses of the drug, pending approval by federal health regulators.
The U.S. authorized the treatment for people ages 12 and older last month.